Headquartered in Cleveland, Ohio, Athersys is a biotech company focused on the development of novel cell therapeutics. With acute respiratory distress syndrome (ARDS) identified as a leading cause of death in COVID-19 patients, Athersys is working fast to launch a pivotal trial of its MultiStem® cell therapy product for the treatment of this life-threatening condition. [Read more…]
Pluristem Therapeutics expects to treat more patients in Israel in the near future
It is in discussions with regulatory agencies in the U.S. and Europe to define its clinical strategy for COVID-19
What are the most promising drugs, antibodies, and vaccines in development against COVID-19? Our team sifted through hundreds of articles and research papers to identify the most promising ones. In most cases, these drugs, vaccines and antibodies are already in use for other diseases, making it easier to leverage them in the fight against the Coronavirus. [Read more…]
AlloVir’s proprietary technology is designed to develop virus specific T-cell therapies with potential to treat and prevent several devastating viral diseases with each single cell therapy product.
CAMBRIDGE, Mass & HOUSTON- AlloVir, a late-clinical stage T-cell immunotherapy company, today announced the expansion of its research and development collaboration with Baylor College of Medicine to include the discovery and development of allogeneic, off-the-shelf, virus specific T-cell therapies to combat SARS-CoV-2, the virus that causes COVID-19. [Read more…]
What is the Cymerus™ technology and how could it potentially assist in the battle against Coronavirus cases on a global basis? Cymerus™ is a stem cell manufacturing platform being developed by Cynata Therapeutics Limited (ASX: CYP), an Australian regenerative medicine company.
The proprietary technology utilizes induced pluripotent stem cells (iPSCs) originating from an adult donor as the starting material for generating mesenchymoangioblasts (MCAs). It then differentiates these cells into mesenchymal stem cells (MSCs). [Read more…]